5-26　ⓔ文献

  1. Raynaud M: Local asphyxia and symmetrical gangrene of extrimities, New sydenham Society, 1862.

  2. Wigley FM: Clinical practice: Raynaud’s phenomenon. N Engl J Med, 2002; 347: 1001–1008.

  3. Herrick AL: Pathogenesis of Raynaud’s phenomenon. Rheumatology, 2005; 44: 587–596.

  4. Bakst R, Merola JF, et al: Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol, 2008; 59: 633–653.

  5. Baumhäkel M, Böhm M: Recent achievements in the management of Raynaud’s phenomenon. Vasc Health Risk Manag, 2010; 6: 207–214.

  6. Susol E, MacGregor AJ, et al: A two–stage, genome–wide screen for susceptibility loci in primary Raynaud’s phenomenon. Arthritis Rheum, 2000; 43: 1641–1646.

  7. Munir S, Freidin MB, et al: Association of Raynaud’s phenomenon with a polymorphism in the NOS1 gene. PloS One, 2018; 13: e0196279.

  8. Thompson AE, Shea B, et al: Calcium–Channel Blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum, 2001; 41: 1844–1847.

  9. Wigley FM, Korn JH, et al: Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis. Arthritis Rheum, 1998; 41: 670–677.

  10. Kohn JH, Mayes M, et al: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum, 2004; 50: 3985–3993.

  11. Dziadzio M, Denton CP, et al: Losartan therapy for Raynaud’s phenomenon and scleroderma. Arthritis Rheum, 1999; 42: 2646–2655.

  12. Matucci-Cerinic M, Denton CP, et al: Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS–2 randomised, double–blind, placebo–controlled study. Ann Rheum Dis, 2011; 70: 32–38.

  13. Asad U, Austin B, et al: Botulinum toxin in the long–term treatment of refractory Raynaud’s phenomenon. J Drugs Dermatol, 2019; 18: 943–945.